Saturday 17 October 2026
Export VRTX’s income statement to Excel — free account
Vertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.
499.39
9.36
−1.84%
Follow VRTX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
29.31 | 0.00 | 29.27 | 22.04 | 24.13 | 22.68 | 47.91 | 20.11 | 142.91 | 0.00 |
Piotroski F-Score |
8 | 3 | 3 | 7 | 6 | 8 | 6 | 5 | 8 | 5 |
P/S ratio |
9.66 | 9.42 | 10.73 | 8.20 | 7.47 | 9.89 | 13.50 | 13.83 | 15.29 | 10.77 |
Altman Z-Score |
12.06 | 11.55 | 14.39 | 12.94 | 12.43 | 14.09 | 16.27 | 14.64 | 14.30 | 5.37 |
P/FCF ratio |
36.30 | 0.00 | 31.73 | 18.66 | 23.50 | 20.51 | 37.62 | 35.87 | 51.04 | 102.06 |
Altman Z″-Score (non-manufacturers) |
7.50 | 5.89 | 9.23 | 10.01 | 8.97 | 8.34 | 5.85 | 4.55 | 0.36 | (2.77) |
Beneish M-Score |
(2.17) | (2.23) | (2.18) | (2.42) | (2.34) | (2.36) | (2.09) | 1.61 | (3.32) | (2.69) |
P/Operating CF |
232.78 | 177.65 | 451.37 | 67.92 | 56.88 | 124.92 | 126.03 | 133.95 | 167.26 | 126.62 |
P/B ratio |
6.21 | 6.33 | 6.02 | 5.27 | 5.60 | 7.07 | 9.24 | 9.50 | 18.63 | 13.69 |
Price to Tangible BV |
6.76 | 7.16 | 6.77 | 5.99 | 6.51 | 8.43 | 12.00 | 9.61 | 19.39 | 18.26 |
EV/Sales |
9.14 | 8.91 | 9.66 | 7.08 | 6.58 | 8.96 | 12.79 | 13.08 | 14.81 | 10.38 |
EV/EBITDA |
25.03 | 0.00 | 23.76 | 14.18 | 17.15 | 18.74 | 40.81 | 56.32 | 199.57 | 247.62 |
EV/Operating CF |
30.22 | (199.26) | 26.96 | 15.30 | 18.87 | 17.08 | 33.92 | 31.37 | 43.61 | 74.81 |
EV/FCF |
34.36 | (100.36) | 28.57 | 16.10 | 20.71 | 18.57 | 35.63 | 33.92 | 49.43 | 98.38 |
Quick Ratio |
2.24 | 2.17 | 3.60 | 4.46 | 4.04 | 4.02 | 3.33 | 3.19 | 2.94 | 2.12 |
Current Ratio |
2.90 | 2.69 | 3.99 | 4.83 | 4.46 | 4.33 | 3.61 | 3.43 | 3.28 | 2.31 |
Net Debt/EBITDA |
(1.51) | 233.58 | (2.70) | (2.32) | (2.41) | (2.06) | (2.51) | (3.66) | (8.15) | (9.27) |
Debt/Assets |
0.00% | 0.50% | 1.65% | 2.37% | 3.80% | 4.59% | 6.47% | 9.31% | 16.47% | 28.35% |
Debt/Equity |
0.00 | 0.01 | 0.02 | 0.03 | 0.05 | 0.06 | 0.09 | 0.13 | 0.29 | 0.61 |
Asset Turnover |
0.50 | 0.49 | 0.48 | 0.57 | 0.60 | 0.62 | 0.57 | 0.62 | 0.77 | 0.63 |
Operating CF/Net income |
0.92 | 0.92 | 0.98 | 1.24 | 1.13 | 1.20 | 1.33 | 0.61 | 3.21 | (2.11) |
Capex/Depreciation |
(2.09) | (2.34) | (1.43) | (1.38) | (1.87) | (2.37) | (0.71) | (1.32) | (1.62) | (0.92) |
Interest Coverage |
313.78 | (7.61) | 86.89 | 78.60 | 45.24 | 49.08 | 20.47 | 8.76 | 1.78 | 0.12 |
| 22.54% | (3.15%) | 22.99% | 27.67% | 24.93% | 36.71% | 22.37% | 64.74% | 15.59% | (9.22%) | |
| 16.41% | (2.37%) | 17.71% | 21.04% | 18.60% | 27.02% | 16.16% | 42.83% | 8.18% | (4.15%) | |
ROIC |
21.63% | (1.40%) | 35.54% | 75.52% | 56.37% | 69.55% | 26.58% | 21.48% | 14.33% | 0.92% |
Return on Tangible Assets |
44.62% | (7.38%) | 30.79% | 28.64% | 27.51% | 37.59% | 27.80% | 59.32% | 10.01% | (6.45%) |
Average Days of Receivables |
62.43 | 53.31 | 57.82 | 58.94 | 54.78 | 52.08 | 55.55 | 49.07 | 41.26 | 42.96 |
Research and Development Expense of Revenue |
32.58% | 32.94% | 32.05% | 28.44% | 25.58% | 26.51% | 42.15% | 46.48% | 53.23% | 61.55% |
Selling, General and Administrative Expense of Revenue |
14.61% | 13.29% | 11.52% | 10.58% | 11.09% | 12.42% | 15.82% | 18.30% | 19.93% | 25.43% |
Intangible Assets out of Total Assets |
0.06 | 0.08 | 0.08 | 0.09 | 0.10 | 0.12 | 0.17 | 0.01 | 0.02 | 0.12 |
Share Based Compensation of Revenue |
5.72% | 6.34% | 5.89% | 5.50% | 5.83% | 6.92% | 8.66% | 10.67% | 11.78% | 14.14% |
Graham Net Nets |
0.04 | 0.03 | 0.08 | 0.12 | 0.11 | 0.08 | 0.05 | 0.05 | 0.03 | 0.01 |
Graham Number |
159.40 | 0.00 | 146.80 | 125.96 | 89.58 | 88.54 | 49.37 | 56.87 | 14.06 | 0.00 |
Earnings Yield |
3.41% | (0.51%) | 3.42% | 4.54% | 4.14% | 4.41% | 2.09% | 4.97% | 0.70% | (0.63%) |
Free Cash Flow Yield |
2.76% | (0.94%) | 3.15% | 5.36% | 4.26% | 4.88% | 2.66% | 2.79% | 1.96% | 0.98% |
Revenue per Share |
46.94 | 42.73 | 38.30 | 34.87 | 29.39 | 23.89 | 16.22 | 11.98 | 10.00 | 6.96 |
Operating CF per Share |
14.20 | (1.91) | 13.73 | 16.13 | 10.26 | 12.52 | 6.11 | 5.00 | 3.40 | 0.96 |
Capex per Share |
(1.71) | (1.88) | (1.00) | (0.80) | (0.91) | (1.00) | (0.29) | (0.38) | (0.40) | (0.23) |
Free Cash Flow per Share |
12.49 | (3.79) | 12.72 | 15.33 | 9.35 | 11.52 | 5.82 | 4.62 | 3.00 | 0.73 |
Cash per Share |
25.84 | 23.71 | 43.53 | 42.09 | 29.20 | 25.63 | 14.84 | 12.46 | 8.39 | 6.06 |
Shareholders Equity per Share |
73.00 | 63.63 | 68.22 | 54.33 | 39.19 | 33.44 | 23.71 | 17.44 | 8.21 | 5.47 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
73.00 | 63.63 | 68.22 | 54.33 | 39.19 | 33.44 | 23.71 | 17.44 | 8.21 | 5.47 |
Free Cash Flow |
3,193.80 | (978.00) | 3,278.90 | 3,925.20 | 2,408.50 | 2,993.70 | 1,493.90 | 1,174.84 | 745.52 | 179.54 |
Working Capital |
7,339.80 | 6,031.80 | 10,596.80 | 10,492.70 | 7,418.60 | 6,255.90 | 3,488.00 | 2,722.82 | 1,841.70 | 1,039.00 |
Capital Expenditures |
(437.60) | (485.40) | (258.40) | (204.70) | (235.00) | (259.80) | (75.40) | (95.45) | (99.42) | (56.56) |
Net Current Asset Value |
4,223.80 | 3,472.80 | 8,994.40 | 8,996.60 | 6,228.10 | 5,068.40 | 2,589.61 | 2,032.41 | 1,145.26 | 272.94 |
EV/EBIT |
26.29 | 0.00 | 24.88 | 14.67 | 17.93 | 19.46 | 44.45 | 62.74 | 298.99 | 1,777.69 |
Capex to Sales |
0.04 | 0.04 | 0.03 | 0.02 | 0.03 | 0.04 | 0.02 | 0.03 | 0.04 | 0.03 |
Price to Operating Income |
27.78 | 0.00 | 27.63 | 17.01 | 20.34 | 21.50 | 46.93 | 66.34 | 308.76 | 1,844.21 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.14 | 0.17 | 0.16 | 0.13 | 0.11 | 0.11 | 0.14 | 0.09 | 0.08 | 0.09 |
Cash ROIC |
12.64% | (4.32%) | 11.24% | 15.62% | 13.28% | 18.85% | 14.32% | 14.35% | 15.81% | 4.93% |
Accounts Receivable Turnover |
6.55 | 6.95 | 6.57 | 6.93 | 7.49 | 8.17 | 7.98 | 8.82 | 10.33 | 9.10 |
Accounts Payable Turnover |
3.78 | 3.94 | 3.77 | 4.33 | 5.17 | 6.07 | 5.52 | 4.43 | 4.06 | 3.09 |
Inventory Turnover |
1.14 | 1.57 | 2.10 | 2.66 | 2.85 | 3.28 | 3.75 | 3.47 | 2.90 | 3.12 |
Average Days of Payables |
102.05 | 98.49 | 105.52 | 102.68 | 78.72 | 76.89 | 58.37 | 98.92 | 98.17 | 106.57 |
Days of Inventory on Hand |
372.85 | 287.47 | 213.64 | 155.62 | 142.54 | 139.20 | 111.61 | 110.84 | 148.36 | 134.59 |
Average Receivables |
1,831.10 | 1,586.40 | 1,502.80 | 1,289.50 | 1,011.10 | 759.46 | 521.60 | 345.52 | 240.85 | 187.10 |
Average Payables |
437.35 | 388.95 | 334.40 | 249.45 | 175.05 | 121.36 | 99.30 | 92.49 | 67.72 | 68.20 |
Average Inventory |
1,446.10 | 972.10 | 599.70 | 406.85 | 316.95 | 224.15 | 145.93 | 118.10 | 94.72 | 67.41 |
Average Assets |
24,088.10 | 22,631.70 | 20,440.55 | 15,791.70 | 12,592.15 | 10,035.13 | 7,282.18 | 4,895.96 | 3,221.40 | 2,697.69 |
Average Common Equity |
17,537.70 | 16,995.00 | 15,746.55 | 12,006.35 | 9,393.40 | 7,386.02 | 5,260.22 | 3,238.75 | 1,690.25 | 1,215.91 |
Columns are period end dates